The world's scientific and social network for malaria professionals
Subscribe to free Newsletter | 11149 malaria professionals are enjoying the free benefits of MalariaWorld today

artesunate-amodiaquine

Efficacy of artesunate-amodiaquine and artemether-lumefantrine for uncomplicated Plasmodium falciparum malaria in Madagascar, 2018

November 20, 2021 - 14:11 -- Open Access
Author(s): 
Catherine M. Dentinger, Tovonahary Angelo Rakotomanga, C. Arsène Ratsimbasoa, et al.
Reference: 
Malaria Journal 2021 20:432, 3 November 2021

Since 2005, artemisinin-based combination therapy (ACT) has been recommended to treat uncomplicated falciparum malaria in Madagascar. Artesunate-amodiaquine (ASAQ) and artemether-lumefantrine (AL) are the first- and second-line treatments, respectively. A therapeutic efficacy study was conducted to assess ACT efficacy and molecular markers of anti-malarial resistance.

Therapeutic efficacy of artesunate-amodiaquine and artemether-lumefantrine and polymorphism in Plasmodium falciparum kelch13-propeller gene in Equatorial Guinea

June 23, 2021 - 14:06 -- Open Access
Author(s): 
Matilde Riloha Rivas, Marian Warsame, Pascal Ringwald, et al.
Reference: 
Malaria Journal 2021 20:275, 22 June 2021

Artesunate-amodiaquine (ASAQ) and artemether-lumefantrine (AL) are the currently recommended first- and second-line therapies for uncomplicated Plasmodium falciparum infections in Equatorial Guinea. This study was designed to evaluate the efficacy of these artemisinin-based combinations and detect mutations in P. falciparum kelch13-propeller domain gene (Pfkelch13).

Clinical and in vitro resistance of Plasmodium falciparum to artesunate-amodiaquine in Cambodia

May 29, 2020 - 14:34 -- Open Access
Author(s): 
Mairet-Khedim M, Leang R, Witkowski B, et al.
Reference: 
Clin Infect Dis. 2020 May 27:ciaa628

Artesunate-amodiaquine is a potential therapy for uncomplicated malaria in Cambodia.

The duration of chemoprophylaxis against malaria after treatment with artesunate-amodiaquine and artemether-lumefantrine and the effects of pfmdr1 86Y and pfcrt 76T: a meta-analysis of individual patient data

March 2, 2020 - 15:29 -- Open Access
Author(s): 
Bretscher MT, Dahal P, Okell LC, et al.
Reference: 
BMC Med. 2020 Feb 25; 18(1):47

The majority of Plasmodium falciparum malaria cases in Africa are treated with the artemisinin combination therapies artemether-lumefantrine (AL) and artesunate-amodiaquine (AS-AQ), with amodiaquine being also widely used as part of seasonal malaria chemoprevention programs combined with sulfadoxine-pyrimethamine. While artemisinin derivatives have a short half-life, lumefantrine and amodiaquine may give rise to differing durations of post-treatment prophylaxis, an important additional benefit to patients in higher transmission areas.

NOT Open Access | Pharmacokinetics and Ex vivo Antimalarial Activity of Artesunate-Amodiaquine plus Methylene Blue in Healthy Volunteers

January 27, 2020 - 13:47 -- NOT Open Access
Author(s): 
Anh CX, Chavchich M, Birrell GW, Van Breda K, Travers T, Rowcliffe K, Lord AR, Shanks GD, Edstein MD
Reference: 
Antimicrob Agents Chemother. 2020 Jan 6. pii: AAC.01441-19

High artesunate combination therapy (ACT) treatment failures of Plasmodium falciparum malaria in Southeast Asia has led to triple drug strategies to extend the useful life of ACTs. In this study, we determined whether methylene blue (MB) alters the pharmacokinetics of artesunate-amodiaquine (ASAQ) and enhances the ex vivo antimalarial activity of ASAQ. In an open labelled, randomized cross-over design, a single oral dose of either ASAQ (200 mg AS/540 mg AQ) alone or with MB (325 mg MB) was administered to 15 healthy Vietnamese volunteers. Serial blood samples were collected up to 28 days after dosing.


Clinical determinants of early parasitological response to ACTs in African patients with uncomplicated falciparum malaria: a literature review and meta-analysis of individual patient data

September 9, 2015 - 15:38 -- Open Access
Author(s): 
WWARN Artemisinin based Combination Therapy (ACT) Africa Baseline Study Group
Reference: 
BMC Medicine 2015, 13:212

This study was designed to establish the baseline values for clearance in patients from Sub-Saharan African countries with uncomplicated malaria treated with artemisinin-based combination therapies (ACTs).

Maximizing antimalarial efficacy and the importance of dosing strategies

May 12, 2015 - 15:57 -- Open Access
Author(s): 
James G Beeson, Philippe Boeuf and Freya JI Fowkes
Reference: 
BMC Medicine 2015, 13:110

In the most recent study, an analysis of clinical trials of artesunate-amodiaquine, widely used among children in Africa, revealed a superior efficacy for fixed-dose combination tablets compared to loose non-fixed dose combinations.

Efficacy of chloroquine for the treatment of Plasmodium vivax in the Saharan zone in Mauritania

February 25, 2015 - 15:29 -- Open Access
Author(s): 
Mohamed Ould Ahmedou Salem, Yeslim Mohamed Lemine, Sidi Lebatt, et al.
Reference: 
Malaria Journal 2015, 14:39 (28 January 2015)

The aim of the present study was to evaluate the clinical efficacy and tolerance of chloroquine to treat P. vivax malaria in Mauritanian patients.

Not Open Access | Efficacy and Safety of Triple Combination Therapy With Artesunate-Amodiaquine–Methylene Blue for Falciparum Malaria in Children: A Randomized Controlled Trial in Burkina Faso

February 16, 2015 - 15:42 -- NOT Open Access
Author(s): 
Boubacar Coulibaly, Michael Pritsch, Olaf Müller, et al.
Reference: 
J Infect Dis. (2015) 211 (5): 689-697.

The combination of MB with an artemisinin-based combination therapy has been confirmed to be effective against the gametocytes of P. falciparum.

A randomized trial of artesunate-amodiaquine versus artemether-lumefantrine in Ghanaian paediatric sickle cell and non-sickle cell disease patients with acute uncomplicated malaria

September 25, 2014 - 12:07 -- Open Access
Author(s): 
Adjei GO, Goka BQ, Enweronu-Laryea CC, Rodrigues OP, Renner L, Sulley AM, Alifrangis M, Khalil I, Kurtzhals JA
Reference: 
Malaria Journal 2014, 13 :369 (19 September 2014)

Children with SCD and acute uncomplicated malaria (n = 60) were randomized to treatment with artesunate-amodiaquine (AA), or artemether-lumefantrine (AL). A comparison group of non-SCD children (HbAA genotype; n = 59) with uncomplicated malaria were also randomized to treatment with AA or AL.

Pages

Subscribe to RSS - artesunate-amodiaquine